T1	CHEM 51 63	azitromicina
#1	AnnotatorNotes T1	C0052796; azithromycin; Organic Chemical · Antibiotic
T2	PROC 69 77	prevenir
#2	AnnotatorNotes T2	C0199176; Prophylactic treatment; Therapeutic or Preventive Procedure
T3	DISO 91 102	sibilancias
#3	AnnotatorNotes T3	C0043144; Wheezing; Sign or Symptom | C0425483; Whistling respiration; Finding
T4	PROC 167 177	ingresados
#4	AnnotatorNotes T4	C0021629; Institutionalization; Health Care Activity | C0184666; Hospital admission; Health Care Activity
T5	DISO 182 201	bronquiolitis aguda
#5	AnnotatorNotes T5	C0001311; Acute bronchiolitis; Disease or Syndrome
T6	DISO 203 205	BA
#6	AnnotatorNotes T6	C0001311; Acute bronchiolitis; Disease or Syndrome
T7	CHEM 229 241	azitromicina
#7	AnnotatorNotes T7	C0052796; azithromycin; Organic Chemical · Antibiotic
T8	CHEM 243 246	AZT
#8	AnnotatorNotes T8	C0052796; azithromycin; Organic Chemical · Antibiotic
T9	CHEM 278 292	interleucina 8
#9	AnnotatorNotes T9	C0079633; interleukin-8; Immunologic Factor · Amino Acid, Peptide, or Protein
T10	PROC 294 298	IL-8
#10	AnnotatorNotes T10	C4700790; interleukin-8 in serum or plasma; Laboratory Procedure
T11	ANAT 303 308	suero
#11	AnnotatorNotes T11	C0229671; Serum; Body Substance | C0588987; Serum product; Body Substance
T12	ANAT 314 326	fluido nasal
#12	AnnotatorNotes T12	C1444694; Nasal fluid; Body Substance
T13	DISO 369 380	sibilancias
#13	AnnotatorNotes T13	C0043144; Wheezing; Sign or Symptom | C0425483; Whistling respiration; Finding
T15	PROC 645 654;664 676	detección nasofaríngea
T16	ANAT 664 676	nasofaríngea
#14	AnnotatorNotes T16	C0027442; Nasopharynx; Body Part, Organ, or Organ Component | C1268975; Entire nasopharynx; Body Part, Organ, or Organ Component
T17	PROC 686 745	inmunofluorescencia directa de virus respiratorio sincitial
#15	AnnotatorNotes T17	C4737839; respiratory syncytial virus antigen detection by immunofluorescence; Laboratory Procedure
T18	PROC 850 870	ingreso hospitalario
#16	AnnotatorNotes T18	C0184666; Hospital admission; Health Care Activity
T19	DISO 1003 1045	infección del tracto respiratorio inferior
#17	AnnotatorNotes T19	C0149725; Lower respiratory tract infection; Disease or Syndrome
T20	DISO 1079 1087	síntomas
#18	AnnotatorNotes T20	C1457887; Symptoms; Sign or Symptom
T21	PROC 1146 1160	aleatorización
#19	AnnotatorNotes T21	C0034656; Randomization; Research Activity
T22	DISO 1215 1237	síntomas respiratorios
#20	AnnotatorNotes T22	C0037090; Signs and Symptoms, Respiratory; Sign or Symptom
T23	DISO 1295 1306	sibilancias
#21	AnnotatorNotes T23	C0043144; Wheezing; Sign or Symptom | C0425483; Whistling respiration; Finding
T24	PROC 1308 1319	tratamiento
#22	AnnotatorNotes T24	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T25	CHEM 1331 1342	corticoides
#23	AnnotatorNotes T25	C0001617; Adrenal Cortex Hormones; Hormone · Organic Chemical · Pharmacologic Substance
T26	PROC 1969 1997	concentración sérica de IL-8
#24	AnnotatorNotes T26	C4700790; interleukin-8 in serum or plasma; Laboratory Procedure
T27	PROC 2074 2101	se asignaron aleatoriamente
#25	AnnotatorNotes T27	C0034656; Randomization; Research Activity
T28	PROC 1376 1387	tratamiento
#26	AnnotatorNotes T28	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T29	PROC 1457 1468	tratamiento
#27	AnnotatorNotes T29	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T30	DISO 1481 1504	reflujo gastroesofágico
#28	AnnotatorNotes T30	C0017168; Gastroesophageal reflux disease; Disease or Syndrome | C4317146; Acid reflux; Finding
T31	PROC 1521 1544	tratamiento antibiótico
#29	AnnotatorNotes T31	C0199779; Administration of antibiotic; Therapeutic or Preventive Procedure | C0338237; Antibiotic therapy; Therapeutic or Preventive Procedure
T32	PROC 1599 1610	tratamiento
#30	AnnotatorNotes T32	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T33	DISO 1676 1740	enfermedades crónicas pulmonares, cardiacas, renales o hepáticas
T34	ANAT 1698 1708	pulmonares
#31	AnnotatorNotes T34	C0024109; Lung; Body Part, Organ, or Organ Component | C1278908; Entire lung; Body Part, Organ, or Organ Component
T35	ANAT 1710 1719	cardiacas
#32	AnnotatorNotes T35	C0018787; Heart; Body Part, Organ, or Organ Component | C1281570; Entire heart; Body Part, Organ, or Organ Component
T36	ANAT 1721 1728	renales
#33	AnnotatorNotes T36	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T37	ANAT 1731 1740	hepáticas
#34	AnnotatorNotes T37	C0023884; Liver; Body Part, Organ, or Organ Component | C1278929; Entire liver; Body Part, Organ, or Organ Component
T38	DISO 1787 1790	VRS
#35	AnnotatorNotes T38	C0035235; Respiratory Syncytial Virus Infections; Disease or Syndrome
T39	PROC 2465 2498	niveles séricos y nasales de IL-8
T40	ANAT 1983 1989	sérica
#36	AnnotatorNotes T40	C0229671; Serum; Body Substance | C0588987; Serum product; Body Substance
T41	CHEM 1993 1997	IL-8
#37	AnnotatorNotes T41	C0079633; interleukin-8; Immunologic Factor · Amino Acid, Peptide, or Protein
T42	CHEM 2036 2039	AZT
#38	AnnotatorNotes T42	C0052796; azithromycin; Organic Chemical · Antibiotic
T43	PROC 2042 2054	Intervención
#39	AnnotatorNotes T43	C0184661; Interventional procedure; Therapeutic or Preventive Procedure
T44	PROC 2113 2139	aleatorización por bloques
#40	AnnotatorNotes T44	C4687722; Block Randomization; Research Activity
T45	CHEM 2189 2192	AZT
#41	AnnotatorNotes T45	C0052796; azithromycin; Organic Chemical · Antibiotic
T46	CHEM 2267 2270	AZT
#42	AnnotatorNotes T46	C0052796; azithromycin; Organic Chemical · Antibiotic
T47	PROC 2659 2669	entrevista
#43	AnnotatorNotes T47	C0683518; patient interview; Health Care Activity
T48	PROC 2924 2947	niveles séricos de IL-8
#44	AnnotatorNotes T48	C4700790; interleukin-8 in serum or plasma; Laboratory Procedure
T49	PROC 2352 2359	placebo
#45	AnnotatorNotes T49	C0032042; Placebos; Therapeutic or Preventive Procedure
T50	CHEM 2404 2407	AZT
#46	AnnotatorNotes T50	C0052796; azithromycin; Organic Chemical · Antibiotic
T51	ANAT 2473 2480	séricos
#47	AnnotatorNotes T51	C0229671; Serum; Body Substance | C0588987; Serum product; Body Substance
T52	ANAT 2483 2490	nasales
#48	AnnotatorNotes T52	C0028429; Nose; Body Part, Organ, or Organ Component
T53	CHEM 2494 2498	IL-8
#49	AnnotatorNotes T53	C0079633; interleukin-8; Immunologic Factor · Amino Acid, Peptide, or Protein
T54	CHEM 2542 2545	AZT
#50	AnnotatorNotes T54	C0052796; azithromycin; Organic Chemical · Antibiotic
T55	DISO 2577 2579	BA
#51	AnnotatorNotes T55	C0001311; Acute bronchiolitis; Disease or Syndrome
T56	PROC 2629 2632	ECA
#52	AnnotatorNotes T56	C0206035; Controlled Clinical Trials, Randomized; Research Activity
T57	PROC 261 292	concentración de interleucina 8
#53	AnnotatorNotes T57	C4700790; interleukin-8 in serum or plasma; Laboratory Procedure
T58	CHEM 2831 2834	AZT
#54	AnnotatorNotes T58	C0052796; azithromycin; Organic Chemical · Antibiotic
T59	PROC 2850 2857	placebo
#55	AnnotatorNotes T59	C0032042; Placebos; Therapeutic or Preventive Procedure
T60	ANAT 2932 2939	séricos
#56	AnnotatorNotes T60	C0229671; Serum; Body Substance | C0588987; Serum product; Body Substance
T61	CHEM 2943 2947	IL-8
#57	AnnotatorNotes T61	C0079633; interleukin-8; Immunologic Factor · Amino Acid, Peptide, or Protein
T62	PROC 2977 2980	ECA
#58	AnnotatorNotes T62	C0206035; Controlled Clinical Trials, Randomized; Research Activity
T63	CHEM 3001 3005	IL-8
#59	AnnotatorNotes T63	C0079633; interleukin-8; Immunologic Factor · Amino Acid, Peptide, or Protein
T64	PROC 3076 3090	aleatorización
#60	AnnotatorNotes T64	C0034656; Randomization; Research Activity
T65	CHEM 3104 3108	IL-8
#61	AnnotatorNotes T65	C0079633; interleukin-8; Immunologic Factor · Amino Acid, Peptide, or Protein
T66	PROC 3191 3198	placebo
#62	AnnotatorNotes T66	C0032042; Placebos; Therapeutic or Preventive Procedure
T67	CHEM 3203 3206	AZT
#63	AnnotatorNotes T67	C0052796; azithromycin; Organic Chemical · Antibiotic
T68	ANAT 3246 3259	nasofaríngeos
#64	AnnotatorNotes T68	C0027442; Nasopharynx; Body Part, Organ, or Organ Component | C1268975; Entire nasopharynx; Body Part, Organ, or Organ Component
T69	CHEM 3263 3267	IL-8
#65	AnnotatorNotes T69	C0079633; interleukin-8; Immunologic Factor · Amino Acid, Peptide, or Protein
T70	PROC 3284 3295	seguimiento
#66	AnnotatorNotes T70	C1522577; Follow up; Health Care Activity | C0420316; Other follow-up; Health Care Activity
T71	PROC 3464 3475	seguimiento
#67	AnnotatorNotes T71	C1522577; Follow up; Health Care Activity | C0420316; Other follow-up; Health Care Activity
T72	PROC 3599 3610	seguimiento
#68	AnnotatorNotes T72	C1522577; Follow up; Health Care Activity | C0420316; Other follow-up; Health Care Activity
T73	CHEM 3808 3811	AZT
#69	AnnotatorNotes T73	C0052796; azithromycin; Organic Chemical · Antibiotic
T74	ANAT 3854 3867	nasofaríngeos
#70	AnnotatorNotes T74	C0027442; Nasopharynx; Body Part, Organ, or Organ Component | C1268975; Entire nasopharynx; Body Part, Organ, or Organ Component
T75	CHEM 3871 3875	IL-8
#71	AnnotatorNotes T75	C0079633; interleukin-8; Immunologic Factor · Amino Acid, Peptide, or Protein
T76	PROC 3996 4007	seguimiento
#72	AnnotatorNotes T76	C1522577; Follow up; Health Care Activity | C0420316; Other follow-up; Health Care Activity
T77	PROC 211 225	administración
#73	AnnotatorNotes T77	C1533734; Administration procedure; Therapeutic or Preventive Procedure
T78	PROC 426 504	ensayo clínico aleatorizado (ECA) piloto, doble ciego y controlado con placebo
#74	AnnotatorNotes T78	C0206034; Clinical Trials, Randomized; Research Activity + C0031928; Pilot Projects; Research Activity + C0013072; Double-Blind Method; Research Activity + C0599724; placebo controlled study; Research Activity · Intellectual Product
T79	PROC 2982 3005	niveles basales de IL-8
T80	ANAT 736 745	sincitial
#75	AnnotatorNotes T80	C0017526; Giant Cells; Cell
T81	PROC 3093 3108	niveles de IL-8
#76	AnnotatorNotes T81	C4700790; interleukin-8 in serum or plasma; Laboratory Procedure
T82	ANAT 1017 1045	tracto respiratorio inferior
#77	AnnotatorNotes T82	C0035243; Respiratory Tract Infections; Disease or Syndrome
T83	CHEM 1392 1409	broncodilatadores
#78	AnnotatorNotes T83	C0006280; Bronchodilator Agents; Pharmacologic Substance
T84	ANAT 1489 1504	gastroesofágico
#79	AnnotatorNotes T84	C0744316; gastroesophageal; Body Location or Region
T85	CHEM 1533 1544	antibiótico
#80	AnnotatorNotes T85	C0003232; Antibiotics; Antibiotic
T86	CHEM 1615 1625	macrólidos
#81	AnnotatorNotes T86	C0003240; Macrolide Antibiotics; Antibiotic · Organic Chemical | C0282563; Macrolides; Organic Chemical · Pharmacologic Substance
T87	PROC 3238 3267	niveles nasofaríngeos de IL-8
T88	PROC 2164 2176	intervención
#82	AnnotatorNotes T88	C0184661; Interventional procedure; Therapeutic or Preventive Procedure
T89	PROC 3825 3875	concentración de los niveles nasofaríngeos de IL-8
T92	LIVB 161 166	niños
#83	AnnotatorNotes T92	C0008059; Child; Age Group
T94	LIVB 594 599	niños
#84	AnnotatorNotes T94	C0008059; Child; Age Group
T95	Age 620 640	entre uno y 18 meses
T96	LIVB 717 745	virus respiratorio sincitial
#85	AnnotatorNotes T96	C0035236; Respiratory syncytial virus; Virus
T97	Duration 884 918	dos estaciones invernales seguidas
T98	Date 920 924	2011
T99	Date 930 934	2012
T100	Duration 1171 1185	los siete días
T101	Route 1365 1374	inhalados
#86	AnnotatorNotes T101	C0205535; Inhalation Route of Drug Administration; Functional Concept
T102	Duration 1548 1571	las últimas dos semanas
T103	Duration 1573 1587	cuatro semanas
T105	Duration 1645 1657	< 36 semanas
T106	Duration 1689 1697	crónicas
#87	AnnotatorNotes T106	C0205191; chronic; Temporal Concept
T107	LIVB 1781 1786	niños
#88	AnnotatorNotes T107	C0008059; Child; Age Group
T110	LIVB 1896 1901	niños
#89	AnnotatorNotes T110	C0008059; Child; Age Group
T111	LIVB 2015 2020	niños
#90	AnnotatorNotes T111	C0008059; Child; Age Group
T112	LIVB 2155 2176	grupo de intervención
#91	AnnotatorNotes T112	C2986530; Intervention Group; Population Group | C5205743; Experimental Group; Population Group
T113	Form 2196 2206	suspensión
#92	AnnotatorNotes T113	C4724031; Suspension Dosage Form; Biomedical or Dental Material
T114	Route 2207 2211	oral
#93	AnnotatorNotes T114	C1527415; Oral Route of Drug administration; Functional Concept
T115	Dose 2213 2221	10 mg/kg
T116	Frequency 2222 2236	una vez al día
T117	Duration 2245 2255	siete días
T118	Route 2271 2275	oral
#94	AnnotatorNotes T118	C1527415; Oral Route of Drug administration; Functional Concept
T119	Dose 2277 2284	5 mg/kg
T120	Frequency 2285 2299	una vez al día
T121	Duration 2314 2324	siete días
T122	LIVB 2326 2339	grupo control
#95	AnnotatorNotes T122	C0009932; Control Groups; Group
T124	Duration 2588 2602	las 50 semanas
T125	LIVB 2676 2682	padres
#96	AnnotatorNotes T125	C0030551; parent; Family Group
T127	Date 2951 2961	octavo día
T130	Date 3271 3280	el día 15
T131	Neg_cue 3312 3314	no
T132	Date 3318 3328	octavo día
T134	LIVB 3412 3417	niños
#97	AnnotatorNotes T134	C0008059; Child; Age Group
T137	LIVB 3547 3552	niños
#98	AnnotatorNotes T137	C0008059; Child; Age Group
T140	LIVB 572 592	Población de estudio
#99	AnnotatorNotes T140	C2348561; Study Population (group); Population Group
T142	LIVB 747 750	VRS
#100	AnnotatorNotes T142	C0035236; Respiratory syncytial virus; Virus
T144	ANAT 1224 1237	respiratorios
#101	AnnotatorNotes T144	C0035237; Respiratory System; Body System | C1269561; Entire respiratory system; Body System
T90	Date 115 131	posbronquiolitis
T91	Date 399 415	posbronquiolitis
T14	Duration 1116 1143	igual o menor de cinco días
T93	Date 3448 3460	la semana 50
T108	Date 3583 3595	la semana 50
T109	Date 925 927	12
T123	Date 935 937	13
T126	PHYS 1633 1644	gestacional
#102	AnnotatorNotes T126	C0032961; Pregnancy; Organism Function
T128	LIVB 2060 2073	participantes
#103	AnnotatorNotes T128	C4554048; Study Participant; Population Group
T129	PROC 1628 1644	edad gestacional
#104	AnnotatorNotes T129	C4040272; Assessment of fetal gestational age; Health Care Activity
T133	LIVB 2341 2343	GC
#105	AnnotatorNotes T133	C0009932; Control Groups; Group
T135	LIVB 3156 3158	GC
#106	AnnotatorNotes T135	C0009932; Control Groups; Group
T136	LIVB 3053 3055	GC
#107	AnnotatorNotes T136	C0009932; Control Groups; Group
T138	LIVB 3012 3014	GI
#108	AnnotatorNotes T138	C2986530; Intervention Group; Population Group | C5205743; Experimental Group; Population Group
T139	LIVB 3130 3132	GI
#109	AnnotatorNotes T139	C2986530; Intervention Group; Population Group | C5205743; Experimental Group; Population Group
T141	LIVB 2178 2180	GI
#110	AnnotatorNotes T141	C2986530; Intervention Group; Population Group | C5205743; Experimental Group; Population Group
T143	LIVB 3494 3496	GI
#111	AnnotatorNotes T143	C2986530; Intervention Group; Population Group | C5205743; Experimental Group; Population Group
T145	LIVB 3752 3754	GI
#112	AnnotatorNotes T145	C2986530; Intervention Group; Population Group | C5205743; Experimental Group; Population Group
T146	LIVB 3629 3631	GI
#113	AnnotatorNotes T146	C2986530; Intervention Group; Population Group | C5205743; Experimental Group; Population Group
T147	LIVB 3518 3520	GC
#114	AnnotatorNotes T147	C0009932; Control Groups; Group
T148	LIVB 3652 3654	GC
#115	AnnotatorNotes T148	C0009932; Control Groups; Group
T149	ANAT 723 735	respiratorio
#116	AnnotatorNotes T149	C1283798; Entire respiratory tract; Body Part, Organ, or Organ Component | C0282335; Respiratory tract structure; Body Part, Organ, or Organ Component
A1	Population_data T94 Age
A4	Population_data T107 Age
A5	Population_data T110 Age
A6	Population_data T111 Age
A7	Population_data T92 Age
A8	Population_data T134 Age
A9	Assertion T132 Negated
A10	Population_data T137 Age
A2	Status T23 History_of
A3	Status T24 History_of
A11	Status T25 History_of
A12	Status T28 History_of
A13	Status T83 History_of
A14	Status T31 History_of
A15	Status T32 History_of
A16	Status T86 History_of
R1	Used_for Arg1:T1 Arg2:T2	
T104	Neg_cue 1 3	No
T150	CONC 36 47	recomienden
A17	Assertion T150 Negated
#117	AnnotatorNotes T150	C0034866; Recommendation; Idea or Concept
R2	Negation Arg1:T104 Arg2:T150	
R3	Before Arg1:T2 Arg2:T3	
T151	Observation 103 114	recurrentes
#118	AnnotatorNotes T151	C0679254; Disease recurrence; Finding
R4	Has_Quantifier_or_Qualifier Arg1:T3 Arg2:T151	
R5	Overlap Arg1:T3 Arg2:T90	
R6	Overlap Arg1:T1 Arg2:T90	
R7	Experiences Arg1:T92 Arg2:T4	
R8	Experiences Arg1:T92 Arg2:T5	
R11	Experiences Arg1:T92 Arg2:T6	
R12	Experiences Arg1:T92 Arg2:T77	
R13	Used_for Arg1:T7 Arg2:T77	
R14	Used_for Arg1:T8 Arg2:T77	
R15	Experiences Arg1:T92 Arg2:T57	
R16	Experiences Arg1:T92 Arg2:T10	
R17	Location_of Arg1:T11 Arg2:T57	
R18	Location_of Arg1:T12 Arg2:T10	
R19	Overlap Arg1:T13 Arg2:T91	
T152	Observation 381 392	recurrentes
#119	AnnotatorNotes T152	C0679254; Disease recurrence; Finding
R20	Has_Quantifier_or_Qualifier Arg1:T13 Arg2:T152	
R21	Experiences Arg1:T92 Arg2:T13	
R22	Before Arg1:T5 Arg2:T13	
R23	Before Arg1:T6 Arg2:T13	
R28	Overlap Arg1:T8 Arg2:T91	
R29	Overlap Arg1:T7 Arg2:T91	
T153	Quantifier_or_Qualifier 523 535	hospitalario
#120	AnnotatorNotes T153	C1510665; Hospital environment; Qualitative Concept
R30	Has_Age Arg1:T140 Arg2:T95	
R31	Has_Age Arg1:T94 Arg2:T95	
R32	Location_of Arg1:T16 Arg2:T15	
T154	Result_or_Value 655 663	positiva
R33	Has_Result_or_Value Arg1:T15 Arg2:T154	
R34	Location_of Arg1:T149 Arg2:T96	
R35	Location_of Arg1:T80 Arg2:T96	
R36	Location_of Arg1:T80 Arg2:T142	
R37	Location_of Arg1:T149 Arg2:T142	
R38	Experiences Arg1:T140 Arg2:T15	
R39	Experiences Arg1:T140 Arg2:T17	
R40	Experiences Arg1:T94 Arg2:T15	
R41	Experiences Arg1:T94 Arg2:T17	
R42	Experiences Arg1:T140 Arg2:T18	
R43	Has_Duration_or_Interval Arg1:T18 Arg2:T97	
R44	Experiences Arg1:T94 Arg2:T18	
R45	After Arg1:T18 Arg2:T98	
R46	After Arg1:T18 Arg2:T99	
R47	Before Arg1:T18 Arg2:T109	
R48	Before Arg1:T18 Arg2:T123	
R51	Location_of Arg1:T82 Arg2:T19	
T155	Quantifier_or_Qualifier 984 999	primer episodio
R52	Has_Quantifier_or_Qualifier Arg1:T19 Arg2:T155	
T156	CONC 1097 1103	inicio
#121	AnnotatorNotes T156	C0439659; Beginning; Temporal Concept
R53	Overlap Arg1:T20 Arg2:T156	
R54	Has_Duration_or_Interval Arg1:T20 Arg2:T14	
R55	Overlap Arg1:T21 Arg2:T100	
R56	After Arg1:T21 Arg2:T22	
R57	Before Arg1:T20 Arg2:T21	
R58	Location_of Arg1:T144 Arg2:T22	
R59	Causes Arg1:T19 Arg2:T20	
R60	Causes Arg1:T19 Arg2:T22	
R61	Used_for Arg1:T25 Arg2:T24	
T157	Quantifier_or_Qualifier 1349 1359	sistémicos
#122	AnnotatorNotes T157	C0205373; Systemic; Functional Concept
R62	Has_Quantifier_or_Qualifier Arg1:T25 Arg2:T157	
R63	Has_Route_or_Mode Arg1:T25 Arg2:T101	
R64	Used_for Arg1:T83 Arg2:T28	
T158	CONC 1420 1428	episodio
#123	AnnotatorNotes T158	C0332189; Episode of; Temporal Concept
R65	Before Arg1:T28 Arg2:T158	
R66	Location_of Arg1:T84 Arg2:T30	
A18	Status T85 History_of
R67	Used_for Arg1:T85 Arg2:T31	
R68	Has_Duration_or_Interval Arg1:T85 Arg2:T102	
R69	Has_Duration_or_Interval Arg1:T86 Arg2:T103	
R70	Used_for Arg1:T86 Arg2:T32	
R71	Has_Duration_or_Interval Arg1:T126 Arg2:T105	
R72	Has_Duration_or_Interval Arg1:T33 Arg2:T106	
R73	Location_of Arg1:T34 Arg2:T33	
R74	Location_of Arg1:T35 Arg2:T33	
R75	Location_of Arg1:T36 Arg2:T33	
R76	Location_of Arg1:T37 Arg2:T33	
R77	Experiences Arg1:T107 Arg2:T38	
T159	Result_or_Value 1791 1800	positivos
R78	Has_Result_or_Value Arg1:T38 Arg2:T159	
T160	Neg_cue 1827 1829	no
T161	Observation 1830 1864	cumplir los criterios de selección
#124	AnnotatorNotes T161	C1302261; Patient eligible for clinical trial; Finding (?)
R79	Negation Arg1:T160 Arg2:T161	
A19	Assertion T161 Negated
R81	Location_of Arg1:T40 Arg2:T26	
R82	Experiences Arg1:T111 Arg2:T26	
R83	Experiences Arg1:T111 Arg2:T42	
R85	Experiences Arg1:T128 Arg2:T43	
R86	Before Arg1:T27 Arg2:T43	
R87	Before Arg1:T44 Arg2:T43	
R88	Before Arg1:T44 Arg2:T88	
R89	Before Arg1:T27 Arg2:T88	
R90	Experiences Arg1:T112 Arg2:T88	
R91	Experiences Arg1:T112 Arg2:T43	
R92	Experiences Arg1:T141 Arg2:T88	
R93	Experiences Arg1:T141 Arg2:T43	
R94	Experiences Arg1:T141 Arg2:T45	
R95	Experiences Arg1:T128 Arg2:T45	
R96	Has_Drug_Form Arg1:T45 Arg2:T113	
R97	Has_Route_or_Mode Arg1:T45 Arg2:T114	
R98	Has_Dose_or_Strength Arg1:T45 Arg2:T115	
R99	Has_Frequency Arg1:T45 Arg2:T116	
R100	Has_Duration_or_Interval Arg1:T45 Arg2:T117	
R101	Before Arg1:T45 Arg2:T46	
R102	Has_Route_or_Mode Arg1:T46 Arg2:T118	
R103	Has_Dose_or_Strength Arg1:T46 Arg2:T119	
R104	Has_Frequency Arg1:T46 Arg2:T120	
R105	Has_Duration_or_Interval Arg1:T46 Arg2:T121	
R106	Experiences Arg1:T141 Arg2:T46	
R108	Experiences Arg1:T112 Arg2:T46	
R109	Experiences Arg1:T112 Arg2:T45	
R107	Experiences Arg1:T128 Arg2:T46	
R110	Experiences Arg1:T128 Arg2:T49	
R111	Experiences Arg1:T122 Arg2:T49	
R112	Experiences Arg1:T133 Arg2:T49	
R113	Experiences Arg1:T128 Arg2:T50	
R114	Experiences Arg1:T112 Arg2:T50	
R115	Experiences Arg1:T141 Arg2:T50	
R116	Has_Duration_or_Interval Arg1:T49 Arg2:T121	
R117	Has_Duration_or_Interval Arg1:T49 Arg2:T117	
R118	Has_Frequency Arg1:T49 Arg2:T120	
R119	Has_Frequency Arg1:T49 Arg2:T116	
R120	Location_of Arg1:T52 Arg2:T39	
R121	Location_of Arg1:T51 Arg2:T39	
R124	Experiences Arg1:T125 Arg2:T47	
R125	Before Arg1:T56 Arg2:T124	
T162	PROC 2719 2748	análisis de medidas repetidas
#125	AnnotatorNotes T162	C0871881; repeated measures; Research Activity
T163	CONC 2750 2775	análisis de la covarianza
#126	AnnotatorNotes T163	C0814908; ancova; Quantitative Concept
T164	CONC 2778 2801	curvas de supervivencia
#127	AnnotatorNotes T164	C1720944; Kaplan-Meier Survival Curves; Quantitative Concept (?)
T165	Neg_cue 2859 2861	no
T166	CONC 2874 2885	disminución
A20	Assertion T166 Negated
#128	AnnotatorNotes T166	C0547047; Decrease; Quantitative Concept
R126	Negation Arg1:T165 Arg2:T166	
R128	Location_of Arg1:T60 Arg2:T48	
R129	Overlap Arg1:T48 Arg2:T127	
T167	CONC 2966 2980	inicio del ECA
#129	AnnotatorNotes T167	C2349982; Study start time; Temporal Concept 
R131	After Arg1:T48 Arg2:T167	
R130	Experiences Arg1:T138 Arg2:T79	
R132	Experiences Arg1:T138 Arg2:T58	
R133	Experiences Arg1:T136 Arg2:T59	
R134	Overlap Arg1:T79 Arg2:T64	
R135	Overlap Arg1:T79 Arg2:T167	
R137	Experiences Arg1:T138 Arg2:T48	
R138	Experiences Arg1:T136 Arg2:T79	
R139	Experiences Arg1:T136 Arg2:T48	
R140	Experiences Arg1:T139 Arg2:T58	
R141	Experiences Arg1:T135 Arg2:T59	
R142	Experiences Arg1:T139 Arg2:T81	
R143	Experiences Arg1:T135 Arg2:T81	
R145	Before Arg1:T64 Arg2:T59	
R146	Before Arg1:T64 Arg2:T58	
R147	Location_of Arg1:T68 Arg2:T87	
R150	Overlap Arg1:T87 Arg2:T130	
R151	Overlap Arg1:T70 Arg2:T130	
R152	Before Arg1:T66 Arg2:T70	
R153	Before Arg1:T67 Arg2:T70	
R154	Negation Arg1:T131 Arg2:T132	
R155	Overlap Arg1:T87 Arg2:T132	
R156	Overlap Arg1:T70 Arg2:T132	
R157	Overlap Arg1:T71 Arg2:T93	
R158	Overlap Arg1:T72 Arg2:T108	
R159	Location_of Arg1:T74 Arg2:T89	
R162	Overlap Arg1:T89 Arg2:T76	
R163	Before Arg1:T27 Arg2:T45	
R164	Before Arg1:T27 Arg2:T46	
R165	Before Arg1:T27 Arg2:T49	
R166	Before Arg1:T27 Arg2:T50	
R167	Before Arg1:T44 Arg2:T45	
R168	Before Arg1:T44 Arg2:T46	
R169	Before Arg1:T44 Arg2:T49	
R170	Before Arg1:T44 Arg2:T50	
#130	AnnotatorNotes T154	C1446409; Positive; Finding
#131	AnnotatorNotes T159	C1446409; Positive; Finding
T168	Neg_cue 1252 1261	exclusión
R171	Negation Arg1:T168 Arg2:T23	
A21	Assertion T23 Negated
A22	Assertion T24 Negated
R172	Negation Arg1:T168 Arg2:T24	
A23	Assertion T25 Negated
R173	Negation Arg1:T168 Arg2:T25	
A24	Assertion T157 Negated
R174	Negation Arg1:T168 Arg2:T157	
R175	Negation Arg1:T168 Arg2:T101	
A25	Assertion T101 Negated
A26	Assertion T28 Negated
R176	Negation Arg1:T168 Arg2:T28	
R177	Negation Arg1:T168 Arg2:T83	
A27	Assertion T83 Negated
A28	Assertion T29 Negated
R178	Negation Arg1:T168 Arg2:T29	
R179	Negation Arg1:T168 Arg2:T31	
A29	Assertion T31 Negated
A30	Assertion T85 Negated
R180	Negation Arg1:T168 Arg2:T85	
A31	Assertion T102 Negated
R181	Negation Arg1:T168 Arg2:T102	
A32	Assertion T103 Negated
R182	Negation Arg1:T168 Arg2:T103	
A33	Assertion T32 Negated
R183	Negation Arg1:T168 Arg2:T32	
A34	Assertion T86 Negated
R184	Negation Arg1:T168 Arg2:T86	
A35	Assertion T129 Negated
A36	Assertion T105 Negated
R185	Negation Arg1:T168 Arg2:T129	
R186	Negation Arg1:T168 Arg2:T105	
A37	Assertion T33 Negated
R187	Negation Arg1:T168 Arg2:T33	
T169	Quantifier_or_Qualifier 2886 2916	estadísticamente significativa
A38	Assertion T169 Negated
#132	AnnotatorNotes T169	C0237881; Statistical Significance; Quantitative Concept
R136	Has_Quantifier_or_Qualifier Arg1:T166 Arg2:T169	
R188	Negation Arg1:T165 Arg2:T169	
T170	Spec_cue 154 156	si
T171	CONC 248 257	disminuye
A39	Assertion T171 Speculated
#133	AnnotatorNotes T171	C0547047; Decrease; Quantitative Concept
R189	Speculation Arg1:T170 Arg2:T171	
T172	Observation 2529 2535	efecto
#134	AnnotatorNotes T172	C1518681; Outcome of Therapy; Finding (?)
R9	Causes Arg1:T54 Arg2:T172	
R10	Before Arg1:T58 Arg2:T166	
R26	Before Arg1:T59 Arg2:T166	
R24	Before Arg1:T73 Arg2:T76	
#135	AnnotatorNotes T33	C0746102; Chronic lung disease; Disease or Syndrome | C1290386; Chronic heart disease; Disease or Syndrome | C1561643; Chronic Kidney Diseases; Disease or Syndrome | C0341439; Chronic Liver Disease; Disease or Syndrome
A40	Experiencer T107 Patient
A41	Experiencer T110 Patient
A42	Experiencer T111 Patient
A43	Experiencer T128 Patient
A44	Experiencer T112 Patient
A45	Experiencer T141 Patient
A46	Experiencer T133 Patient
A47	Experiencer T122 Patient
A48	Experiencer T125 Family_member
A49	Experiencer T138 Patient
A50	Experiencer T136 Patient
A51	Experiencer T139 Patient
A52	Experiencer T135 Patient
A53	Experiencer T134 Patient
A54	Experiencer T143 Patient
A55	Experiencer T147 Patient
A56	Experiencer T137 Patient
A57	Experiencer T146 Patient
A58	Experiencer T148 Patient
A59	Experiencer T145 Patient
A60	Experiencer T92 Patient
A61	Experiencer T94 Patient
A62	Experiencer T140 Patient
